Roles of IL-10 in ocular inflammations: A review

Ocular Immunology and Inflammation

Volumn 20, Issue 6, 2012, Pages 406-418

  Ghasemi, Hassan ^a   Ghazanfari, Tooba ^a   Yaraee, Roya ^a   Owlia, Parviz ^a   Hassan, Zuhair Mohammad ^b   Faghihzadeh, Soghrat ^b  

^a SHAHED UNIVERSITY   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Angiogenesis; Chemokine; Cytokine; IL 10; Ocular inflammations; Review

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR2; CYTOKINE; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AQUEOUS HUMOR; CHOROID; CONJUNCTIVA; CORNEA; CYTOKINE RELEASE; EYE INFLAMMATION; HUMAN; NONHUMAN; ORBIT; RETINA; RETINOBLASTOMA; REVIEW; SYSTEMATIC REVIEW; VITREOUS BODY;

ANIMALS; ANTERIOR CHAMBER; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-10; T-LYMPHOCYTES; UVEITIS;

EID: 84870858987     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2012.723109     Document Type: Review

References (163)

1. Mosmann TR. Properties and functions of interleukin-10. Adv Immunol 1994;56:1-26.:1-26.
2. Gesser B, Leffers H, Jinquan T. et al. Identification of functional domains on human interleukin 10. Proc Natl Acad Sci U S A 1997 December 23;94(26):14620-5.
3. Holan V, Vitova A, Pindjakova J, Krulova M, Zajicova A, Filipec M. Corneal stromal cells selectively inhibit production of anti-inflammatory cytokines by activated T cells. Clin Exp Immunol 2004 May;136(2):200-6.
4. Dinarello CA. Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 2009 June 4;360(23):2467-70.
5. Bettini M, Vignali DA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 2009 December;21(6):612-8.
6. Salmaggi A, Dufour A, Eoli M et al. Low serum interleukin-10 levels in multiple sclerosis: Further evidence for decreased systemic immunosuppression? J Neurol 1996 January;243(1):13-7.
7. Narverud I, Ueland T, Nenseter MS et al. Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor alpha system and interleukin-10. Atherosclerosis 2011 January;214(1):163-8.
8. Li X, Mai J, Virtue A et al. IL-35 is a novel responsive antiinflammatory cytokine-a new system of categorizing antiinflammatory cytokines. PLoS ONE 2012;7(3):e33628.
9. Chen CY, Shyu AB. AU-rich elements: Characterization and importance in mRNA degradation. Trends Biochem Sci 1995 November;20(11):465-70.
10. Cavaillon JM. Cytokines and macrophages. Biomed Pharmacother 1994;48(10):445-53.
11. Shaykhiev R, Krause A, Salit J et al. Smoking-dependent reprogramming of alveolar macrophage polarization: Implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol 2009 August 15;183(4):2867-83.
12. Yoshida S, Ono M, Shono T et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997 July;17(7):4015-23.
13. Ghasemi H, Ghazanfari T, Yaraee R, Faghihzadeh S, Hassan ZM. Roles of IL-8 in ocular inflammations: A review. Ocul Immunol Inflamm 2011 December;19(6):401-12.
14. de KY, Thillaye-Goldenberg B, Naud MC, Da Costa AV, Auriault C, Verwaerde C. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. Clin Exp Immunol 2002 November;130(2):212-23.
15. Sabat R, Wallace E, Endesfelder S, Wolk K. IL-19 and IL-20: Two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets 2007 May;11(5):601-12.
16. Sabat R. IL-10 family of cytokines. Cytokine Growth Factor Rev 2010 October;21(5):315-24.
17. Baggiolini M, Dewald B, Moser B. Human chemokines: An update. Annu Rev Immunol 1997;15:675-705. (Pubitemid 27169296)
18. Zhou X, Schmidtke P, Zepp F, Meyer CU. Boosting interleukin-10 production: Therapeutic effects and mechanisms. Curr Drug Targets Immune Endocr Metabol Disord 2005 December;5(4):465-75.
19. Zdanov A. Structural analysis of cytokines comprising the IL-10 family. Cytokine Growth Factor Rev 2010 October;21(5):325-30.
20. Zdanov A. Structural features of the interleukin-10 family of cytokines. Curr Pharm Des 2004;10(31):3873-84. (Pubitemid 39591904)
21. Trivella DB, Ferreira-Junior JR, Dumoutier L, Renauld JC, Polikarpov I. Structure and function of interleukin-22 and other members of the interleukin-10 family. Cell Mol Life Sci 2010 September;67(17):2909-35.
22. Sabat R, Grutz G, Warszawska K et al. Biology of interleukin-10. Cytokine Growth Factor Rev 2010 October;21(5):331-44.
23. Bundoc VG, Keane-Myers A. IL-10 confers protection from mast cell degranulation in a mouse model of allergic conjunctivitis. Exp Eye Res 2007 October;85(4):575-9.
24. McClellan SA, Huang X, Barrett RP, van RN, Hazlett LD. Macrophages restrict Pseudomonas aeruginosa growth, regulate polymorphonuclear neutrophil influx, and balance proand anti-inflammatory cytokines in BALB/c mice. J Immunol 2003 May 15;170(10):5219-27.
25. Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy 2006 June;36(6):777-84.
26. Sano Y, Osawa H, Sotozono C, Kinoshita S. Cytokine expression during orthotopic corneal allograft rejection in mice. Invest Ophthalmol Vis Sci 1998 September;39(10):1953-7.
27. Ozaki A, Fukushima A, Fukata K, Ueno H. Effects of IL-4 and IL-12 on experimental immune-mediated blepharoconjunctivitis in Brown Norway rats. Clin Exp Immunol 2000 October;122(1):28-34.
28. Paolieri F, Battifora M, Riccio AM, Pesce G, Canonica GW, Bagnasco M. Intercellular adhesion molecule-1 on cultured human epithelial cell lines: Influence of proinflammatory cytokines. Allergy 1997 May;52(5):521-31.
29. Stumpf TH, Case R, Shimeld C, Easty DL, Hill TJ. Primary herpes simplex virus type 1 infection of the eye triggers similar immune responses in the cornea and the skin of the eyelids. J Gen Virol 2002 July;83(Pt 7):1579-90. (Pubitemid 34716263)
30. Vavra AK, Laurent CJ, Ngo V, Sweeney JF, Levitt JM. Sulfur mustard primes phagocytosis and degranulation in human polymorphonuclear leukocytes. Int Immunopharmacol 2004 March;4(3):437-45.
31. de Waal MR, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991 October 1;174(4):915-24.
32. Yssel H, de Waal MR, Roncarolo MG et al. IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol 1992 October 1;149(7):2378-84.
33. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993 August 1;151(3):1224-34.
34. Chang CH, Furue M, Tamaki K. B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-gamma or by interleukin-10. Eur J Immunol 1995 February;25(2):394-8.
35. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991 December 1;147(11):3815-22.
36. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993 June 1;81(11):2964-71.
37. de Waal MR, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993 June 1;150(11):4754-65.
38. Peguet-Navarro J, Moulon C, Caux C, biez-Gauthier C, Banchereau J, Schmitt D. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur J Immunol 1994 April;24(4):884-91.
39. Caux C, Massacrier C, Vanbervliet B, Barthelemy C, Liu YJ, Banchereau J. Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. Int Immunol 1994 Aug ust;6(8):1177-85. (Pubitemid 24254121)
40. Bejarano MT, de Waal MR, Abrams JS. et al. Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol 1992 December;4(12):1389-97.
41. Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 1998 April 1;160(7):3188-93.
42. Rousset F, Garcia E, Defrance T et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 1992 March 1;89(5):1890-3.
43. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 1992 March 1;175(3):671-82.
44. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol 2010. pii: 832454. Epub;%2010 Sep 14.:832454.
45. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996 July 1;184(1):19-29.
46. Kube D, Platzer C, von KA et al. Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine 1995 January;7(1):1-7.
47. Cole N, Hume EB, Khan S et al. The corneal response to infection with Staphylococcus aureus in the absence of interleukin-4. Immunol Cell Biol 2007 June;85(4):333-7.
48. Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 2002 December;39(9):531-6.
49. Carson WE, Lindemann MJ, Baiocchi R et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995 June 15;85(12):3577-85.
50. Taga K, Cherney B, Tosato G. IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol 1993 December;5(12):1599-608.
51. Bailey DP, Kashyap M, Bouton LA, Murray PJ, Ryan JJ. Interleukin-10 induces apoptosis in developing mast cells and macrophages. J Leukoc Biol 2006 September;80(3):581-9.
52. Hayes MP, Freeman SL, Donnelly RP. IFN-gamma priming of monocytes enhances LPS-induced TNF production by augmenting both transcription and MRNA stability. Cytokine 1995 July;7(5):427-35.
53. de Waal MR, Figdor CG, Huijbens R et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 1993 December 1;151(11):6370-81.
54. Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci U S A 1989 May;86(10):3803-7.
55. Hagenbaugh A, Sharma S, Dubinett SM et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997 June 16;185(12):2101-10.
56. Walter MR. Structure of interleukin-10/interleukin-10R1 complex: A paradigm for class 2 cytokine activation. Immunol Res 2002;26(1-3):303-8. (Pubitemid 35177507)
57. Speiran K, Bailey DP, Fernando J et al. Endogenous suppression of mast cell development and survival by IL-4 and IL-10. J Leukoc Biol 2009 May;85(5):826-36.
58. Dickensheets HL, Freeman SL, Smith MF, Donnelly RP. Interleukin-10 upregulates tumor necrosis factor receptor type-II (p75) gene expression in endotoxin-stimulated human monocytes. Blood 1997 November 15;90(10):4162-71.
59. Roy MP, Kim CH, Butcher EC. Cytokine control of memory B cell homing machinery. J Immunol 2002 August 15;169(4):1676-82.
60. Couper KN, Blount DG, Riley EM. IL-10: The master regulator of immunity to infection. J Immunol 2008 May 1;180(9):5771-7.
61. Kotenko SV. The family of IL-10-related cytokines and their receptors: Related, but to what extent? Cytokine Growth Factor Rev 2002 June;13(3):223-40. (Pubitemid 34693176)
62. Carrington LM, Albon J, Anderson I, Kamma C, Boulton M. Differential regulation of key stages in early corneal wound healing by TGF-beta isoforms and their inhibitors. Invest Ophthalmol Vis Sci 2006 May;47(5):1886-94. (Pubitemid 46768268)
63. Sarangi PP, Sehrawat S, Suvas S, Rouse BT. IL-10 and natural regulatory T cells: Two independent anti-inflammatory mechanisms in herpes simplex virus-induced ocular immunopathology. J Immunol 2008 May 1;180(9):6297-306.
64. Li Z, Liu B, Maminishkis A et al. Gene expression profiling in autoimmune noninfectious uveitis disease. J Immunol 2008 October 1;181(7):5147-57.
65. Oh JY, Kim MK, Shin MS et al. The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells 2008 April;26(4):1047-55.
66. Cole N, Krockenberger M, Stapleton F et al. Experimental Pseudomonas aeruginosa keratitis in interleukin-10 gene knockout mice. Infect Immun 2003 March;71(3):1328-36. (Pubitemid 36254318)
67. King WJ, Comer RM, Hudde T, Larkin DF, George AJ. Cytokine and chemokine expression kinetics after corneal transplantation. Transplantation 2000 October 27;70(8):1225-33.
68. Yamagami S, Kawashima H, Endo H et al. Cytokine profiles of aqueous humor and graft in orthotopic mouse corneal transplantation. Transplantation 1998 December 15;66(11):1504-10. (Pubitemid 29014030)
69. Oh JY, Kim MK, Shin MS et al. The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells 2008 April;26(4):1047-55.
70. Klebe S, Sykes PJ, Coster DJ, Krishnan R, Williams KA. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 2001 May 15;71(9):1214-20. (Pubitemid 32507137)
71. Bauer D, Lu M, Wasmuth S et al. Immunomodulation by topical particle-mediated administration of cytokine plasmid DNA suppresses herpetic stromal keratitis without impairment of antiviral defense. Graefes Arch Clin Exp Ophthalmol 2006 February;244(2):216-25.
72. Minagawa H, Sakai Y, Li Y, Ishibashi T, Inomata H, Mori R. Suppression of infectious virus spread and corneal opacification by the combined use of recombinant interferon beta and interleukin-10 following corneal infection with herpes simplex virus-1 in mice. Antiviral Res 1997 November;36(2):99-105.
73. Giavina-Bianchi P, Kalil J, Rizzo LV. Development of an animal model for allergic conjunctivitis: Influence of genetic factors and allergen concentration on immune response. Acta Ophthalmol 2008 September;86(6):670-5.
74. Nivenius E, van dPI, Gafvelin G, Van HM, Montan PG. Conjunctival provocation with airborne allergen in patients with atopic keratoconjunctivitis. Clin Exp Allergy 2012 January;42(1):58-65.
75. Fukushima A, Sumi T, Fukuda K et al. Interleukin 10 and transforming growth factor beta contribute to the development of experimentally induced allergic conjunctivitis in mice during the effector phase. Br J Ophthalmol 2006 December;90(12):1535-41. (Pubitemid 44862577)
76. Narayanan S, Corrales RM, Farley W, McDermott AM, Pflugfelder SC. Interleukin-1 receptor-1-deficient mice show attenuated production of ocular surface inflammatory cytokines in experimental dry eye. Cornea 2008 Aug ust;27(7):811-7.
77. Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948 February;29(1):58-69.
78. Kaplan HJ, Streilein JW. Immune response to immunization via the anterior chamber of the eye. I. F. lymphocyte-induced immune deviation. J Immunol 1977 March;118(3):809-14. (Pubitemid 8070859)
79. Vega JL, Keino H, Masli S. Surgical denervation of ocular sympathetic afferents decreases local transforming growth factor-beta and abolishes immune privilege. Am J Pathol 2009 September;175(3):1218-25.
80. Hori J. Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantation. J Ocul Biol Dis Infor 2008 December;1(2-4):94-100.
81. Streilein JW. Ocular immune privilege: The eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol 2003 August;74(2):179-85.
82. Wang Y, Goldschneider I, O'Rourke J, Cone RE. Blood mononuclear cells induce regulatory NK T thymocytes in anterior chamber-associated immune deviation. J Leukoc Biol 2001 May;69(5):741-6.
83. Sheibani N, Sorenson CM, Cornelius LA, Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem Biophys Res Commun 2000 January 7;267(1):257-61.
84. Lin HH, Faunce DE, Stacey M et al. The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J Exp Med 2005 May 16;201(10):1615-25.
85. D'Orazio TJ, Niederkorn JY. Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID). Immunology 1998 September;95(1):47-55.
86. Faunce DE, Stein-Streilein J. NKT cell-derived RANTES recruits APCs and CD8+ T cells to the spleen during the generation of regulatory T cells in tolerance. J Immunol 2002 July 1;169(1):31-8.
87. Sonoda KH, Faunce DE, Taniguchi M, Exley M, Balk S, Stein-Streilein J. NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J Immunol 2001 January 1;166(1):42-50.
88. Nakamura T, Sonoda KH, Faunce DE et al. CD4+ NKT cells, but not conventional CD4+ T cells, are required to generate efferent CD8+ T regulatory cells following antigen inoculation in an immune-privileged site. J Immunol 2003 August 1;171(3):1266-71.
89. Skelsey ME, Mayhew E, Niederkorn JY. CD25+, interleukin-10-producing CD4+ T cells are required for suppressor cell production and immune privilege in the anterior chamber of the eye. Immunology 2003 September;110(1):18-29.
90. Skelsey ME, Mellon J, Niederkorn JY. Gamma delta T cells are needed for ocular immune privilege and corneal graft survival. J Immunol 2001 April 1;166(7):4327-33.
91. Ashour HM, Niederkorn JY. Gammadelta T cells promote anterior chamber-associated immune deviation and immune privilege through their production of IL-10. J Immunol 2006 December 15;177(12):8331-7.
92. D'Orazio TJ, Niederkorn JY. A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol 1998 March 1;160(5):2089-98.
93. D'Orazio TJ, Niederkorn JY. The nature of antigen in the eye has a profound effect on the cytokine milieu and resultant immune response. Eur J Immunol 1998 May;28(5):1544-53.
94. Tsukahara R, Takeuchi M, Akiba H et al. Critical contribution of CD80 and CD86 to induction of anterior chamber-associated immune deviation. Int Immunol 2005 May;17(5):523-30.
95. Agarwal RK, Horai R, Viley AM et al. Abrogation of antiretinal autoimmunity in IL-10 transgenic mice due to reduced T cell priming and inhibition of disease effector mechanisms. J Immunol 2008 April 15;180(8):5423-9.
96. Ke Y, Jiang G, Sun D, Kaplan HJ, Shao H. Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis. Invest Ophthalmol Vis Sci 2008 September;49(9):3999-4007.
97. Taylor AW, Kaplan HJ. Ocular immune privilege in the year 2010: Ocular immune privilege and uveitis. Ocul Immunol Inflamm 2010 December;18(6):488-92.
98. Dace DS, Khan AA, Kelly J, Apte RS. Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development. PLoS ONE 2008;3(10):e3381.
99. Kelly J, Ali KA, Yin J, Ferguson TA, Apte RS. Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J Clin Invest 2007 November;117(11):3421-6.
100. Many MC, Costagliola S, Detrait M, Denef F, Vassart G, Ludgate MC. Development of an animal model of autoimmune thyroid eye disease. J Immunol 1999 April 15;162(8):4966-74.
101. Jabs DA, Prendergast RA, Rorer EM, Hudson AP, Whittum-Hudson JA. Cytokines in autoimmune lacrimal gland disease in MRL/MpJ mice. Invest Ophthalmol Vis Sci 2001 October;42(11):2567-71.
102. Carreno E, Enriquez-de-Salamanca A, Teson M et al. Cytokine and chemokine levels in tears from healthy subjects. Acta Ophthalmol 2010 November;88(7):e250-e258.
103. Uchino E, Sonoda S, Kinukawa N, Sakamoto T. Alteration pattern of tear cytokines during the course of a day: Diurnal rhythm analyzed by multicytokine assay. Cytokine 2006 January 7;33(1):36-40.
104. Uchino E, Sonoda S, Nakao K, Sakamoto T. Alteration of tear cytokine balance by eye closure: Analysis by multicytokine assay. Graefes Arch Clin Exp Ophthalmol 2006 June;244(6):747-9.
105. van Gelderen BE, Van der LA, Peek R et al. Cytokines in aqueous humour and serum before and after corneal transplantation and during rejection. Ophthalmic Res 2000 July;32(4):157-64.
106. Shtein RM, Garcia DD, Musch DC, Elner VM. HSV keratitis: histopathologic predictors of corneal allograft complications. Trans Am Ophthalmol Soc 2008;106:161-8.
107. Boorstein SM, Elner SG, Meyer RF et al. Interleukin-10 inhibition of HLA-DR expression in human herpes stromal keratitis. Ophthalmology 1994 September;101(9):1529-35.
108. Szodoray P, Gal I, Barath S et al. Immunological alterations in newly diagnosed primary Sjogren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines. Scand J Rheumatol 2008 May;37(3):205-12.
109. Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004 December;111(12):2186-92.
110. Atan D, Fraser-Bell S, Plskova J et al. Cytokine polymorphism in noninfectious uveitis. Invest Ophthalmol Vis Sci 2010 August;51(8):4133-42.
111. Paunicka K, Chen PW, Niederkorn JY. Role of IFN-gamma in the establishment of anterior chamber-associated immune deviation (ACAID)-induced CD8+ T regulatory cells. J Leukoc Biol 2012 March;91(3):475-83.
112. Shahram F, Nikoopour E, Rezaei N et al. Association of interleukin-2, interleukin-4 and transforming growth factorbeta gene polymorphisms with Behcet's disease. Clin Exp Rheumatol 2011 July;29(4 Suppl 67):S28YS31.
113. Curnow SJ, Pryce K, Modi N et al. Serum cytokine profiles in Behcet's disease: Is there a role for IL-15 in pathogenesis? Immunol Lett 2008 November 16;121(1):7-12.
114. Plskova J, Greiner K, Muckersie E, Duncan L, Forrester JV. Interferon-alpha: A key factor in autoimmune disease? Invest Ophthalmol Vis Sci 2006 September;47(9):3946-50.
115. Lee YS, madi-Obi A, Yu CR, Egwuagu CE. Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10. Immunology 2011 April;132(4):492-502.
116. Cassoux N, Giron A, Bodaghi B et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. Invest Ophthalmol Vis Sci 2007 July;48(7):3253-9.
117. Cordeiro CA, Moreira PR, Andrade MS et al. Interleukin-10 gene polymorphism (-1082G/A) is associated with toxoplasmic retinochoroiditis. Invest Ophthalmol Vis Sci 2008 May;49(5):1979-82.
118. Lee JH, Lee W, Kwon OH et al. Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Ann Clin Lab Sci 2008;38(4):361-7.
119. Hernandez C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simo R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2005 June;22(6):719-22.
120. Apte RS, Richter J, Herndon J, Ferguson TA. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med 2006 August;3(8):e310.
121. Yoshida A, Elner SG, Bian ZM, Kunkel SL, Lukacs NW, Elner VM. Differential chemokine regulation by Th2 cytokines during human RPE-monocyte coculture. Invest Ophthalmol Vis Sci 2001 June;42(7):1631-8.
122. Chan CC, Whitcup SM, Solomon D, Nussenblatt RB. Interleukin-10 in the vitreous of patients with primary intraocular lymphoma. Am J Ophthalmol 1995 November;120(5):671-3.
123. Chan CC, Buggage RR, Nussenblatt RB. Intraocular lymphoma. Curr Opin Ophthalmol 2002 December;13(6):411-8.
124. Chan CC. Molecular pathology of primary intraocular lymphoma. Trans Am Ophthalmol Soc 2003;101:275-92.
125. Merle-Beral H, Davi F, Cassoux N et al. Biological diagnosis of primary intraocular lymphoma. Br J Haematol 2004 February;124(4):469-73.
126. Chan CC, Rubenstein JL, Coupland SE et al. Primary vitreoretinal lymphoma: A report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 2011;16(11):1589-99.
127. Sasayama T, Nakamizo S, Nishihara M et al. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro Oncol 2012 March;14(3):368-80.
128. Ongkosuwito JV, Feron EJ, van Doornik CE et al. Analysis of immunoregulatory cytokines in ocular fluid samples from patients with uveitis. Invest Ophthalmol Vis Sci 1998 December;39(13):2659-65.
129. Chan CC, Wallace DJ. Intraocular lymphoma: update on diagnosis and management. Cancer Control 2004 September;11(5):285-95.
130. Jahnke K, Thiel E, Abrey LE, Neuwelt EA, Korfel A. Diagnosis and management of primary intraocular lymphoma: An update. Clin Ophthalmol 2007 September;1(3):247-58.
131. Yang D, Hiromatsu Y, Hoshino T, Inoue Y, Itoh K, Nonaka K. Dominant infiltration of T(H)1-type CD4+ T cells at the retrobulbar space of patients with thyroid-associated ophthalmopathy. Thyroid 1999 March;9(3):305-10.
132. Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2000 March;85(3):1194-9.
133. Kumar S, Bahn RS. Relative overexpression of macrophagederived cytokines in orbital adipose tissue from patients with graves' ophthalmopathy. J Clin Endocrinol Metab 2003 September;88(9):4246-50.
134. Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf) 2003 March;58(3):280-7.
135. de KY, Verwaerde C. Cytokines in immunotherapy of experimental uveitis. Int Rev Immunol 2002 March;21(2-3):231-53.
136. Nouri-Aria KT. Recent progress in allergen immunotherapy. Iran J Immunol 2008 March;5(1):1-24.
137. Otasevic L, Gong N, Ritter T, Mergler S, Pleyer U. Effects of spironolactone on corneal allograft survival in the rat. Ophthalmic Res 2007;39(6):325-9. (Pubitemid 350242712)
138. Tumpey TM, Cheng H, Yan XT, Oakes JE, Lausch RN. Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-10. J Leukoc Biol 1998 April;63(4):486-92.
139. Tumpey TM, Elner VM, Chen SH, Oakes JE, Lausch RN. Interleukin-10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1. J Immunol 1994 September 1;153(5):2258-65.
140. McClellan SA, Zhang Y, Barrett RP, Hazlett LD. Substance P promotes susceptibility to Pseudomonas aeruginosa keratitis in resistant mice: Anti-inflammatory mediators downregulated. Invest Ophthalmol Vis Sci 2008 April;49(4):1502-11.
141. Hazlett LD, McClellan SA, Barrett RP, Liu J, Zhang Y, Lighvani S. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci 2007 February;48(2):797-807.
142. Faal N, Bailey RL, Jeffries D et al. Conjunctival FOXP3 expression in trachoma: Do regulatory T cells have a role in human ocular Chlamydia trachomatis infection? PLoS Med 2006 August;3(8):e266.
143. Galatowicz G, Ajayi Y, Stern ME, Calder VL. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo. Clin Exp Allergy 2007 November;37(11):1648-56.
144. Roever AC, Heine G, Zuberbier T, Worm M. Allergenmediated modulation of CD23 expression is interferongamma and interleukin-10 dependent in allergic and non-allergic individuals. Clin Exp Allergy 2003 November; 33(11):1568-75.
145. Robinson DS, Larche M, Durham SR. Tregs and allergic disease. J Clin Invest 2004 November;114(10):1389-97.
146. Shen J, Taylor N, Duncan L et al. Ex vivo adenovirus mediated gene transfection of human conjunctival epithelium. Br J Ophthalmol 2001 July;85(7):861-7.
147. Fang IM, Yang CH, Lin CP, Yang CM, Chen MS. Effects of pyrrolidine dithiocarbamate, an NF-kappaB inhibitor, on cytokine expression and ocular inflammation in experimental autoimmune anterior uveitis. J Ocul Pharmacol Ther 2005 April;21(2):95-106.
148. Rosenbaum JT, Angell E. Paradoxical effects of IL-10 in endotoxin-induced uveitis. J Immunol 1995 October 15;155(8):4090-4.
149. Carrington L, McLeod D, Boulton M. IL-10 and antibodies to TGF-beta2 and PDGF inhibit RPE-mediated retinal contraction. Invest Ophthalmol Vis Sci 2000 April;41(5):1210-6.
150. Saitoh-Ishibashi K, Ishibashi K, Azumi A, Negi A. Analysis of cytokine mRNAs in murine herpes simplex virus type 1 retinitis. Jpn J Ophthalmol 2003 March;47(2):166-72.
151. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002 January;30(1 Suppl):S58YS63. (Pubitemid 34131163)
152. Samolov B, Kvanta A, van dP, I. Delayed neovascularization in inflammation-induced corneal neovascularization in interleukin-10-deficient mice. Acta Ophthalmol 2008 November 25.
153. Rosenkilde MM, Schwartz TW. The chemokine system -a major regulator of angiogenesis in health and disease. APMIS 2004 July;112(7-8):481-95. (Pubitemid 39626055)
154. Di GN, Kumar RK, Coroneo MT, Wakefield D. UVBmediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Invest Ophthalmol Vis Sci 2002 November;43(11):3430-7.
155. Di GN, Wakefield D, Coroneo MT. UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. Invest Ophthalmol Vis Sci 2006 June;47(6):2430-7.
156. Ghasemi H, Ghazanfari T, Yaraee R et al. Evaluation of the tear and serum levels of IL-8 in sulfur mustard intoxicated patients 20 years after exposure. Cutan Ocul Toxicol 2011 October 4.
157. Ghasemi H, Ghazanfari T, Yaraee R et al. Evaluation of relationship between the serum levels of inflammatory mediators and ocular injuries induced by sulfur mustard: Sardasht-Iran Cohort Study. Int Immunopharmacol 2009 December;9(13-14):1494-8.
158. Yoshida S, Yoshida A, Ishibashi T. Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: Implications for retinal neovascularization during post-ischemic inflammation. Graefes Arch Clin Exp Ophthalmol 2004 May;242(5):409-13.
159. Yoshida A, Yoshida S, Ishibashi T, Inomata H. Intraocular neovascularization. Histol Histopathol 1999 October;14(4): 1287-94.
160. Li XY, D'Orazio LT, Niederkorn JY. Role of Th1 and Th2 cells in anterior chamber-associated immune deviation. Immunology 1996 September;89(1):34-40.
161. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy. Immunol Res 2011 December;51(2-3):170-82.
162. Mitra M, Kandalam M, Harilal A et al. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy. Mol Vis 2012;18:290-308. Epub;%2012 Feb 1.:290-308.
163. Mosser DM, Zhang X. Interleukin-10: New perspectives on an old cytokine. Immunol Rev 2008 December;226:205-18: 205-18.